Journal article
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation
Abstract
BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.
METHODS: We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA2DS2VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a …
Authors
Connolly SJ; Karthikeyan G; Ntsekhe M; Haileamlak A; El Sayed A; El Ghamrawy A; Damasceno A; Avezum A; Dans AML; Gitura B
Journal
New England Journal of Medicine, Vol. 387, No. 11, pp. 978–988
Publisher
Massachusetts Medical Society
Publication Date
September 15, 2022
DOI
10.1056/nejmoa2209051
ISSN
0028-4793